Systemic Effects of Cryolipolysis in Central Obese Wome
Phase 1
- Conditions
- Nutritional, Metabolic, Endocrine
- Registration Number
- PACTR201907693335007
- Lead Sponsor
- Ahmed Ebrahim Elerian
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other
- Sex
- Female
- Target Recruitment
- 30
Inclusion Criteria
age ranging between 40 and 50 years with body mass index ranging from 35-4Okg/m2, waist-to-hip ratio between 0.8 to 1.0 and Total cholesterol > 200 mg/dl, LDL > 150 mg/dl, and HDL < 45 mg/dl
Exclusion Criteria
While any patient with previously past history of chronic disease (e.g. diabetes or hypertension), sensory problem and dehydration for any causes or bleeding problem or peptic ulcer and patients receiving weight control drugs was excluded from this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie cryolipolysis-induced metabolic changes in central obesity?
How does cryolipolysis compare to pharmacological agents like GLP-1 agonists in treating visceral adiposity?
Are there specific biomarkers that predict metabolic response to cryolipolysis in postmenopausal women with central obesity?
What are the potential systemic adverse events associated with cryolipolysis in metabolic syndrome patients and their management?
What combination therapies involving cryolipolysis show promise for addressing insulin resistance in central obesity?